Marker Therapeutics gains as patient dosing begins in cancer therapy study

Marker Therapeutics

12/06/2023 16:09

(Updates)
    ** Shares of cancer drug developer Marker Therapeutics Inc
 MRKR.O  rise 25% to $3.14 
    ** Co says first patient dosed in early-stage study of
MT-601, its therapy candidate for lymphoma
    ** Lymphoma is a type of cancer that begins in cells of the
lymph system
    ** Main goal is to evaluate optimum dose, safety, and 
efficacy of MT-601 in patients with various lymphoma subtypes-
MRKR
    ** Preclinical data showed MT-601 prevented growth of
lymphoma cells 
    ** Shares up 18% YTD

 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))